Literature DB >> 16210371

Prevention of programmed hyperleptinemia and hypertension by postnatal dietary omega-3 fatty acids.

Caitlin S Wyrwoll1, Peter J Mark, Trevor A Mori, Ian B Puddey, Brendan J Waddell.   

Abstract

Fetal programming is now recognized as a key determinant of the adult phenotype, with major implications for adult-onset diseases including hypertension. Two mediators of fetal programming are maternal nutrition and fetal glucocorticoid exposure. Recent studies show that postnatal dietary manipulations can exacerbate programming effects, but whether programming effects can be attenuated by postnatal dietary manipulations, and thus provide a possible therapeutic strategy, is unknown. In this study, we tested the hypothesis that a postnatal diet enriched with long-chain omega-3 fatty acids attenuates programmed hyperleptinemia and hypertension. Pregnant rats were treated with dexamethasone (Dex) from d 13 to term, and offspring were cross-fostered to mothers on either a standard diet or a diet high in omega-3 fatty acids and remained on these diets postweaning. Maternal Dex reduced birthweight and delayed the onset of puberty in offspring. Hyperleptinemia (associated with elevated leptin mRNA expression in adipose tissue) and hypertension were evident in offspring by 6 months of age in Dex-exposed animals consuming a standard diet, but these effects were completely blocked by a high omega-3 diet. These results demonstrate for the first time that manipulation of postnatal diet can limit adverse outcomes of fetal programming, with programmed hyperleptinemia and hypertension prevented by a postnatal diet enriched with omega-3 fatty acids. This raises the possibility that dietary supplementation with omega-3 fatty acids may provide a viable therapeutic option for preventing and/or reducing adverse programming outcomes in humans.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16210371     DOI: 10.1210/en.2005-0748

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  31 in total

1.  Developmental programming of the metabolic syndrome - critical windows for intervention.

Authors:  Mark H Vickers
Journal:  World J Diabetes       Date:  2011-09-15

Review 2.  Determinants of early life leptin levels and later life degenerative outcomes.

Authors:  Delia-Marina Alexe; Garyfallia Syridou; Eleni Th Petridou
Journal:  Clin Med Res       Date:  2006-12

Review 3.  How the kidney is impacted by the perinatal maternal environment to develop hypertension.

Authors:  Ana D Paixão; Barbara T Alexander
Journal:  Biol Reprod       Date:  2013-12-19       Impact factor: 4.285

4.  Maternal protein restriction reduces expression of angiotensin I-converting enzyme 2 in rat placental labyrinth zone in late pregnancy.

Authors:  Haijun Gao; Uma Yallampalli; Chandra Yallampalli
Journal:  Biol Reprod       Date:  2012-02-09       Impact factor: 4.285

5.  Uteroplacental insufficiency reduces rat plasma leptin concentrations and alters placental leptin transporters: ameliorated with enhanced milk intake and nutrition.

Authors:  Jessica F Briffa; Rachael O'Dowd; Karen M Moritz; Tania Romano; Lisa R Jedwab; Andrew J McAinch; Deanne H Hryciw; Mary E Wlodek
Journal:  J Physiol       Date:  2017-03-29       Impact factor: 5.182

6.  Protein restriction to pregnant rats increases the plasma levels of angiotensin II and expression of angiotensin II receptors in uterine arteries.

Authors:  Haijun Gao; Uma Yallampalli; Chandra Yallampalli
Journal:  Biol Reprod       Date:  2012-03-19       Impact factor: 4.285

Review 7.  Developmental and Transmittable Origins of Obesity-Associated Health Disorders.

Authors:  Arin K Oestreich; Kelle H Moley
Journal:  Trends Genet       Date:  2017-04-21       Impact factor: 11.639

8.  Pravastatin ameliorates placental vascular defects, fetal growth, and cardiac function in a model of glucocorticoid excess.

Authors:  Caitlin S Wyrwoll; June Noble; Adrian Thomson; Dijana Tesic; Mark R Miller; Eva A Rog-Zielinska; Carmel M Moran; Jonathan R Seckl; Karen E Chapman; Megan C Holmes
Journal:  Proc Natl Acad Sci U S A       Date:  2016-05-16       Impact factor: 11.205

Review 9.  Effect of in utero and early-life conditions on adult health and disease.

Authors:  Peter D Gluckman; Mark A Hanson; Cyrus Cooper; Kent L Thornburg
Journal:  N Engl J Med       Date:  2008-07-03       Impact factor: 91.245

Review 10.  Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy.

Authors:  Miranda D Grounds; Hannah G Radley; Gordon S Lynch; Kanneboyina Nagaraju; Annamaria De Luca
Journal:  Neurobiol Dis       Date:  2008-04-09       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.